Compare Amylx Pharmaceuticals Inc (AMLX) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Lennar Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.45 (market cap $1.98B), while Lennar Corporation trades at $82.95 (market cap $20.25B). The key difference: Lennar Corporation is far larger — about 10.2× Amylx Pharmaceuticals Inc's market cap, and Lennar Corporation pays a 2.37% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | LEN | |
|---|---|---|
Market Cap | $1.98B | $20.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $142.40 |
52-Week Low | $7.64 | $82.30 |
Enterprise Value | $1.70B | $24.13B |
Dividend Yield | — | 2.37% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
